Answers are grounded in this paper and cite their sources.
Among underserved people with HIV with a median of one year of long-acting cabotegravir-rilpivirine use, including those starting with viremia due to adherence challenges, we found higher satisfaction and lower treatment burden compared to daily oral ART, although nearly half preferred another dosing modality and/or a longer dosing interval.
No takes yet. Share an insight, caveat, or question.
Christopoulos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: